Lack of full disclosure: SEBI issues warning letter to Aurobindo Pharma
Aurobindo Pharma Ltd on Monday said it has received a warning letter from capital markets regulator Sebi for non-disclosure of details related to an ongoing audit of one of its manufacturing units in Hyderabad and observations made by the US Food and Drug Administration (USFDA).The letter is in regards to certain disclosures made by the company on the ongoing USFDA audit of company's Unit-1...
Aurobindo Pharma Ltd on Monday said it has received a warning letter from capital markets regulator Sebi for non-disclosure of details related to an ongoing audit of one of its manufacturing units in Hyderabad and observations made by the US Food and Drug Administration (USFDA).
The letter is in regards to certain disclosures made by the company on the ongoing USFDA audit of company's Unit-1 and observations made by the USFDA between the period 2019 to 2022, Aurobindo Pharma Ltd (APL) said in a regulatory filing.
For more details, check out the full story on the link below:
Lack Of Full Disclosure: SEBI Slaps Warning Letter On Aurobindo Pharma
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd